Toxic multinodular goiter overview

Revision as of 13:22, 12 October 2017 by Damola (talk | contribs) (→‎Electrocardiogram)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Toxic multinodular goiter Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Toxic multinodular goiter from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Toxic multinodular goiter overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Toxic multinodular goiter overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Toxic multinodular goiter overview

CDC on Toxic multinodular goiter overview

Toxic multinodular goiter overview in the news

Blogs on Toxic multinodular goiter overview

Directions to Hospitals Treating Toxic multinodular goiter

Risk calculators and risk factors for Toxic multinodular goiter overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

In 1913, Henry Plummer, an American physician was the first to describe toxic multinodular goiter or Plummer's disease. In 1947, Cope, Rawson, and McArthur were the first who described the usage of radioactive iodine to demonstrate a "hot" thyroid nodule.Toxic multinodular goiter is classified into three types- Primary, secondary, tertiary hyperthyroidism.The progression to Toxic multinodular goiter usually involves the somatic gain-of-function mutations in the TSH receptor in autonomousl, toxic adenoma.The incidence of toxic multinodular goiter is estimated to be 4.8 cases per 100,000 population per year. The prevalence of toxic multinodular goiter is 100 cases per 100,000 population and accounts for 5% of all patients with hyperthyroidism. Toxic multinodular goiter commonly affects individuals older than 60 years of age. The frequency of toxic multinodular goiter increases with age. Females are more commonly affected by toxic multinodular goiter than men. Common risk factors in the development of multinodular goiter include female sex,age over 50 years,areas with decreased iodine intake, iodine supplementation, natural goitrogens, vitamin A and iron deficiency,selenium deficiency.Toxic multinodular goiter is diagnosed with a physical examination which shows nodules in the throat and rapid heart rate, among other signs such as diaphoresis and tremors. Blood screening includes tests for elevated T3 and T4 hormone levels that indicate hyperthyroidism. TSH assays are the best initial screening tool for hyperthyroidism.If left untreated, toxic multinodular goiter may progress to develop hyperthyroidism. However, the progression of toxic multinodular goiter is quite slow. Untreated patients initially have a history of thyroid enlargement followed by a long period of subclinical hyperthyroidism. Overt hyperthyroidism occurs late in the course of toxic multinodular goiter. Common complications of toxic multinodular goiter include tachycardia, arrhythmia, atrial fibrillation, heart failure (dilated cardiomyopathy), pulmonary hypertension, facial plethora, inspiratory stridor, hoarseness, dysphagia, bone mineral loss and thyroid storm. Prognosis of toxic multinodular goiter is generally good with treatment. Both surgery and radioactive iodine therapy can confer a moderate long-term risk of hypothyroidism and such patients require lifelong hormone replacement therapy. Toxic multinodular goiter is commonly seen in elderly. The majority of patients with toxic multinodular goiter are asymptomatic. However, they can present with symptoms such as swelling or pain in front of the neck, cough, shortness of breath, hoarseness, Diaphoresis, skin flushing, increased appetite, restlessness, nervousness, [[[heat intolerance]], tremors, palpitations, insomnia, anxiety, menstrual irregularities. Diagnosis of multinodular goiter is made by measurement of serum thyroid-stimulating hormone (TSH) , serum Free T4 test , total thyroxine (T4) and free triiodothyronine (T3).An ECG may be helpful in the diagnosis of hyperthyroidism due to toxic multinodular goiter. Findings on an ECG suggestive of hyperthyroidism due to include sinus tachycardia, higher voltage of P and T waves, elevated amplitude of QRS complex, prolonged P-Q and shortened Q-T intervals. Findings on an x-ray suggestive of multinodular goiter include anterior/superior mediastinal mass, that may be associated with deviation of the trachea and/or cervicothoracic sign.CT scan may be helpful in the diagnosis and fully characterizing the extent of substernal goitre. Findings on CT scan suggestive of multinodular goiter include enlarged and heterogeneous thyroid gland. CT scan is useful in defining the extent of tracheal deviation and compression.CT scan–guided fine needle aspiration biopsy(FNAB) may be helpful. MRI may be helpful in the assessment of extent of substernal goiters. Findings on MRI suggestive of multinodular goiter include enlarged and heterogeneous thyroid gland. Thyroid ultrasonography is the imaging method of choice in the diagnosis of multinodular goiter. Findings on an ultrasonography suggestive of multinodular goiter include more than one nodule including the non-palpable nodules cysts with varying echogenicity. Thyroid ultrasonography helps in assessment of size and number of nodules. Assessment of vascular characteristics of a thyroid nodule with Doppler helps in screening thyroid nodules for malignancy. Radioidodine uptake may be helpful in the diagnosis of multinodular goiter. The mainstay of treatment for Toxic multinodular goiter is Surgery. Patients with symptomatic hyperthyroidism, sub-clinical hyperthyroid patients with expected compilations and patients refusing surgical therapy are treated with beta blockers and anti-thyroid pharmacological groups. Surgery is the mainstay of treatment for Toxic multinodular goiter. Usually, subtotal thyroidectomy is performed but unilateral thyroid lobectomy can also be performed in selected cases. Effective measures for the primary prevention of toxic multinodular goiter include mainly the adequate iodine intake, smoking cessation and also by maintaining normal intake of iron and vitamin A.

Historical Perspective

In the year 40 BC, Pliny, Vitruvius, and Juvenal were the first who documented the prevalence of goiter in the Alps. In 1500, Leonardo da Vinci was the first who recognized and drew the thyroid gland. In 1913, Henry Plummer, an American physician was the first to describe toxic multinodular goiter also known as Plummer's disease. In 1947, Cope, Rawson, and McArthur were the first who described the usage of radioactive iodine to demonstrate a "hot" thyroid nodule.

Classification

Toxic multinodular goiter is classified into three types namely primary, secondary and tertiary hyperthyroidism. Primary hyperthyroidism is further divided into grave’s disease, toxic thyroid nodule, thyroid adenoma, multinodular goiter. Secondary hyperthyroidism is divided into pituitary adenoma, intracranial tumors pressing pituitary gland. Tertiary hyperthyroidism is divided into intracranial tumors or masses involving hypothalamus.

Pathophysiology

The progression to toxic multinodular goiter usually involves the somatic gain-of-function mutations in the TSH receptor in autonomously functioning thyroid nodules.

Causes

The progression to Toxic multinodular goiter usually involves the somatic gain-of-function mutations in the TSH receptor gene.

Differentiating Toxic multinodular goiter from Other Diseases

Toxic multinodular goiter may be differentiated from other thyroid disorders. The most common differentials include grave's disease, thyrotoxic phase of subacute thyroiditis and toxic adenoma.

Epidemiology and Demographics

The incidence of toxic multinodular goiter is estimated to be 4.8 cases per 100,000 population per year. The prevalence of toxic multinodular goiter is 100 cases per 100,000 population and accounts for 5% of all patients with hyperthyroidism. Toxic multinodular goiter commonly affects individuals older than 60 years of age. The frequency of toxic multinodular goiter increases with age. Females are more commonly affected by toxic multinodular goiter than men.

Risk Factors

Common risk factors in the development of multinodular goiter include female sex,age over 50 years,areas with decreased iodine intake,iodine supplementation, natural goitrogens, vitamin A deficiency, iron deficiency and selenium deficiency.

Screening

Toxic multinodular goiter is diagnosed by a physical examination which reveals nodules in the throat, rapid heart rate, diaphoresis, and tremors. Screening includes testing for elevated T3 and T4 hormone levels that indicate hyperthyroidism. TSH assays are the best initial screening tool for hyperthyroidism.

Natural History, Complications, and Prognosis

If left untreated, toxic multinodular goiter may progress to develop hyperthyroidism. However, the progression of toxic multinodular goiter is quite slow. Untreated patients initially have a history of thyroid enlargement followed by a long period of subclinical hyperthyroidism. Overt hyperthyroidism occurs late in the course of toxic multinodular goiter. Common complications of toxic multinodular goiter include tachycardia, arrhythmia, atrial fibrillation, heart failure (dilated cardiomyopathy), pulmonary hypertension, facial plethora, inspiratory stridor, hoarseness, dysphagia, bone mineral loss and thyroid storm. Prognosis of toxic multinodular goiter is generally good with treatment. Both surgery and radioactive iodine therapy can confer a moderate long-term risk of hypothyroidism and such patients require lifelong hormone replacement therapy. Toxic multinodular goiter is commonly seen in elderly. Therefore, in elderly, presence of other conditions may influence the outcome of toxic multinodular goiter.

Diagnosis

History and Symptoms

The majority of patients with toxic multinodular goiter are asymptomatic. However, they can present with symptoms such as swelling or pain in front of the neck, cough, shortness of breath, hoarseness, diaphoresis, skin flushing, increased appetite, restlessness, nervousness, heat intolerance, tremors, palpitations, insomnia, anxiety, menstrual irregularities.

Physical Examination

The clinical features of toxic multinodular hyperthyroidism includes flushing,diaphoresis, smooth skin, onycholysis, hyperpigmentation, thinning of the hair, thyromegaly,lymphadenopathy, lid lag, shortness of breath on exertion, hypoxemia, hypercapnia, tachycardia, atrial fibrillation, weight loss, increased appetite anorexia, dysphagia, increased urinary frequency, enuresis, gynecomastia, reduced libido, erectile dysfunction, psychosis, agitation, and depression,anxiety, restlessness, irritability, and emotional lability, insomnia, confusion, poor orientation and immediate recall, amnesia, and constructional difficulties, peripheral neuropathy, carpal tunnel syndrome, tremors, myopathy, muscle weakness, proximal and distal weakness, deep tendon reflexes are usually normal or increased, osteoporosis and an increased fracture probability.

Laboratory Findings

Diagnosis of multinodular goiter is made by measurement of serum thyroid-stimulating hormone (TSH) , serum Free T4 test , total thyroxine (T4) and free triiodothyronine (T3).

Electrocardiogram

An ECG may be helpful in the diagnosis of hyperthyroidism due to toxic multinodular goiter. Findings on an ECG suggestive of hyperthyroidism due to toxic multinodular goiter include sinus tachycardia, higher voltage of P and T waves, elevated amplitude of QRS complex, prolonged P-Q and shortened Q-T intervals.

X-ray

An x-ray may be helpful in the diagnosis of multinodular goiter. Findings on an x-ray suggestive of multinodular goiter include anterior/superior mediastinal mass, that may be associated with deviation of the trachea and/or cervicothoracic sign.

CT scan

CT scan may be helpful in the diagnosis and fully characterizing the extent of substernal goitre. Findings on CT scan suggestive of multinodular goiter include enlarged and heterogeneous thyroid gland.CT scan is useful in defining the extent of tracheal deviation and compression.CT scan–guided fine needle aspiration biopsy(FNAB) may be helpful.

MRI

MRI is not routinely performed for the diagnosis of multinodular goiter. MRI can help in the assessment of extent of substernal goiters.Findings on MRI suggestive of multinodular goiter include enlarged and heterogeneous thyroid gland.

Ultrasound

Thyroid ultrasonography is the imaging method of choice in the diagnosis of multinodular goiter. Findings on an ultrasonography suggestive of multinodular goiter include more than one nodule including the non-palpable nodules cysts with varying echogenicity. Thyroid ultrasonography helps in assessment of size and number of nodules.Assessment of vascular characteristics of a thyroid nodule with Doppler helps in screening thyroid nodules for malignancy.

Other Imaging Findings

Radioidodine uptake may be helpful in the diagnosis of multinodular goiter. Patchy pattern of increased radionuclide uptake in more than one nodule associated with decreased uptake in the surrounding extranodular thyroid tissue is characteristic of toxic multinodular goiter.

Other Diagnostic Studies

The most important diagnostic test to differentiate thyroid nodules from each other is fine needle aspiration (FNA).

Treatment

Medical Therapy

The mainstay of treatment for Toxic multinodular goiter is Surgery. Patients with symptomatic hyperthyroidism, sub-clinical hyperthyroid patients with expected compilations and patients refusing surgical therapy are treated with beta blockers and anti-thyroid pharmacological groups.

Surgery

Surgery is the mainstay of treatment for Toxic multinodular goiter. Almost all multinodular goiters can be surgically removed through a collar incision. Usually, subtotal thyroidectomy is performed but unilateral thyroid lobectomy can also be performed in selected cases.

Primary Prevention

Effective measures for the primary prevention of toxic multinodular goiter include mainly the adequate iodine intake, smoking cessation and also by maintaining normal intake of iron and vitamin A.

Secondary Prevention

Surgery is recommended for the secondary prevention of toxic multinodular goiter.

References


Template:WikiDoc Sources